Arcutis Biotherapeutics evp Masaru Matsuda sells $1.37M in planned share sale
Open the sourceReported by Investing.com, investing.com, 5 November 2026, by Investing.com
25Impact 25 of 100, routine
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Muhabbit only has the headline for this one. The full report is at investing.com.
Named in this story
Masaru Matsuda, Arcutis Biotherapeutics